Compare CCJ & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | DGX |
|---|---|---|
| Founded | 1987 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 25.9B |
| IPO Year | 1998 | 1996 |
| Metric | CCJ | DGX |
|---|---|---|
| Price | $71.04 | $258.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 17 |
| Target Price | $115.62 | ★ $257.27 |
| AVG Volume (30 Days) | ★ 3.9M | 851.7K |
| Earning Date | 10-30-2026 | 10-22-2026 |
| Dividend Yield | 0.24% | ★ 1.32% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 7.86 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | $15.91 | $4.45 |
| P/E Ratio | $118.32 | ★ $32.93 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $66.06 | $171.18 |
| 52 Week High | $135.24 | $262.00 |
| Indicator | CCJ | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 68.54 |
| Support Level | $66.06 | $226.27 |
| Resistance Level | $123.86 | N/A |
| Average True Range (ATR) | 3.26 | 5.82 |
| MACD | -0.01 | 0.77 |
| Stochastic Oscillator | 25.52 | 86.88 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe and is one of those uranium producers. It has three reportable segments: Uranium, Fuel Services, and Westinghouse, deriving maximum revenue from the Westinghouse segment. The Uranium segment involves the exploration for, mining, milling, purchase, and sale of uranium concentrate, while the Fuel Services segment involves the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. Westinghouse Electric Company provides products and services to nuclear reactors, including outage and maintenance services, engineering support, instrumentation and controls equipment, plant modification, and components and parts.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.